HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda

This article was originally published in The Tan Sheet

Executive Summary

FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.

You may also be interested in...



NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval

FDA’s Nonprescription Drugs Advisory Committee will meet Sept. 4-5 to discuss the scope and safety of testing necessary for OTC sunscreen ingredients. The announcement comes after FDA earlier this year rejected time and extent applications to add new sunscreen actives to the OTC monograph.

FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection

FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen TEA could concern advocates on Capitol Hill and in the industry for using the process for adding ingredients to the OTC sunscreen monograph.

FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling

FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.

Related Content

Topics

UsernamePublicRestriction

Register

RS139737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel